BRAF and thyroid cancer: In this study, we investigate the association of this genetic alteration (somatic mutation in BRAF V600E) and the epigenetic regulation (DNA promoter methylation) in the pathogenesis of thyroid cancer and explore the potential use of these molecular changes in identifying groups of patients for personalized treatment.